Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results

Arcadia Biosciences (NASDAQ:RKDA) posted its quarterly earnings data on Thursday. The basic materials company reported ($2.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($1.53), FiscalAI reports. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $1.90 million. Arcadia Biosciences had a negative return on equity of 113.73% and a negative net margin of 195.94%.

Arcadia Biosciences Trading Down 18.6%

NASDAQ RKDA traded down $0.13 on Thursday, reaching $0.57. 691,056 shares of the company were exchanged, compared to its average volume of 123,671. The stock has a market capitalization of $1.37 million, a P/E ratio of -0.10 and a beta of 0.56. Arcadia Biosciences has a fifty-two week low of $0.50 and a fifty-two week high of $6.71. The business’s fifty day moving average price is $0.73 and its 200 day moving average price is $1.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.